- Employers: Entry-Level Applicants Are Just About Useless
- Walmart vs. Costco: How Do They Really Compare?
- Tesla Pops on GM Rumor (Update 1)
- Putting a Fingerprint on Every Bullet
- Why Apple Sucks as an Investment, but Amazon Doesn't

Vertex's Roadmap to $10 Billion in Cystic Fibrosis Drug Sales
Combinations of various Vertex drugs could benefit 90% of cystic fibrosis patients.
09:00AM 06/11/13

Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)
In a bubbly year for the biotech sector, these five stocks stand out over the rest.
07:00AM 06/11/13

Ampio Blames Shorts But Won't Answer Legitimate Questions About Its Drugs
Ampio attacks critics instead of answering legitimate questions.
12:21PM 06/10/13

Biotech Stock Mailbag: 2013 Clinical Trials Calendar
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
07:00AM 06/07/13

As If Amarin Needs Another Worry, Here Comes A Vascepa FDA Panel
Amarin's president says company is preparing for FDA advisory panel seeking expansion of fish-oil pill's use.
11:10AM 06/06/13

Aveo Fires 140 Workers As Punishment For CEO's Incompetence
The failure of a kidney cancer drug won't stop Aveo executives from cashing future paychecks.
11:06AM 06/05/13

Clovis Doubles on Buzz Over Lung Cancer Drug
Surprisingly strong results for a lung cancer drug have helped Clovis double in value today.
01:31PM 06/03/13

Synta's Lung Cancer Drug Struggles to Remain Relevant
A narrowing of the survival benefit plus competition from anti-PD1s makes Synta's ganetespib success a long shot.
09:18AM 06/03/13

Bristol And Merck's Cancer Drugs Won ASCO. Five Slides Explain Why.
The anti-PD-1s are shrinking tumors like no drugs have done before and investors are really excited.
09:09AM 06/03/13
ASCO '13 Live Blog: Prepping for Monday Trading
Charting the drug and biotech stocks which came out ahead at this weekend's ASCO annual meeting, and those that fell behind.
08:00AM 06/03/13
RSS Feed